Dr. Heinemann Reviews the FIRE-3 Trial Results

Video

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Volker Heinemann, MD, PhD, a professor of medical oncology at the University of Munich in Munich, Germany, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

In the trial, the objective response rate (ORR) was comparable between the two treatments (bevacizumab and cetuximab). However, in patients who received at least 3 cycles of treatment and had one imaging procedure after baseline, a 10% ORR benefit was observed in the cetuximab arm, Heinemann notes.

Read more about this study >>>

<<<

View more from the 2013 ASCO Annual Meeting

Related Videos
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital